Befejeződött1. fázis
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
Key facts
- Where
- Berlin, Frankfurt Am Main, Freiburg im Breisgau és Hamburg, NémetországSee the 4 sites
- Phase
- 1. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Németország
- Charite Universitaetsmedizin Berlin KöRBerlin, NémetországNo longer taking part
- Goethe University FrankfurtFrankfurt Am Main, NémetországNo longer taking part
- Medical Center- University of FreiburgFreiburg im Breisgau, NémetországNo longer taking part
- University Medical Center Hamburg-EppendorfHamburg, NémetországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sitryx Therapeutics Limited
- Trial code
- EU 2025-522216-17-00
- Record updated
- 2026. június 12.